Tolerising Peptide PTL-0901: Phase II

In a total of 129 patients enrolled in the U.K. trial, PTE's Tolerising Peptide reduced hay fever symptoms (p=0.053), reduced combined symptom-medication scores (p=0.058), and delayed the use of rescu...